KLG Stock +78.58% In 3 Months Since We Picked It KLG Stock +78.58% In 3 Months Since We Picked It Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $62.20 $75.66 Monday, 29th Apr 2024 CYTK stock ended at $62.53. This is 4.30% less than the trading day before Friday, 26th Apr 2024. During the day the stock fluctuated 4.50% from a day low at $62.20 to a day high of $65.00.
90 days $61.33 $84.05
52 weeks $25.98 $110.00

Historical Cytokinetics prices

Date Open High Low Close Volume
Apr 29, 2024 $64.95 $65.00 $62.20 $62.53 1 262 621
Apr 26, 2024 $65.11 $66.07 $64.50 $65.34 607 960
Apr 25, 2024 $64.81 $65.42 $64.00 $64.80 934 261
Apr 24, 2024 $65.89 $67.45 $65.68 $66.82 772 079
Apr 23, 2024 $66.72 $68.76 $65.53 $65.57 1 167 152
Apr 22, 2024 $67.90 $67.90 $65.67 $66.29 1 130 373
Apr 19, 2024 $66.88 $67.80 $64.82 $67.55 1 474 255
Apr 18, 2024 $67.50 $68.53 $66.84 $67.00 862 385
Apr 17, 2024 $69.58 $69.90 $67.88 $67.93 1 233 161
Apr 16, 2024 $67.81 $70.52 $66.55 $69.00 946 053
Apr 15, 2024 $71.60 $71.60 $67.48 $68.00 1 490 126
Apr 12, 2024 $73.76 $73.76 $70.61 $71.56 789 372
Apr 11, 2024 $74.99 $75.50 $72.39 $73.19 741 450
Apr 10, 2024 $72.54 $74.94 $72.30 $74.36 803 120
Apr 09, 2024 $74.20 $75.66 $73.43 $75.05 1 211 190
Apr 08, 2024 $73.90 $74.38 $72.55 $74.19 953 333
Apr 05, 2024 $69.21 $73.21 $68.43 $72.71 976 544
Apr 04, 2024 $71.69 $72.31 $68.72 $69.18 715 558
Apr 03, 2024 $70.27 $71.43 $70.00 $70.92 574 388
Apr 02, 2024 $71.19 $72.72 $70.35 $70.97 997 255
Apr 01, 2024 $69.78 $73.16 $68.90 $73.02 1 347 535
Mar 28, 2024 $71.41 $71.86 $69.96 $70.11 1 611 905
Mar 27, 2024 $71.40 $73.18 $69.88 $71.41 1 879 574
Mar 26, 2024 $69.00 $74.67 $68.28 $71.15 3 998 598
Mar 25, 2024 $67.75 $69.40 $67.64 $68.73 969 189
Click to get the best stock tips daily for free!

About Cytokinetics

Cytokinetics Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in pati... CYTK Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT